ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1374	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Screening (PDQ®)–Health Professional Version	For stomach (gastric) cancer, there is no standard or routine screening test for the general U.S. population. Review the evidence on the benefits and harms of screening for gastric cancer using barium-meal photofluorography, gastric endoscopy, or serum pepsinogen in this expert-reviewed summary.	immigrant ethnic populations 0.555723 routine screening 0.545026 population-based screening 0.55023 major type 0.538572 gastric adenomatous polyps 0.695374 versus unscreened individuals 0.55595 atrophic gastritis 0.615129 H. pylori 0.564647 distal stomach 0.538456 gastric cancer worldwide 0.720749 gastric carcinoma. 0.66881 diffuse type. 0.56645 pepsinogen levels 0.550707 gastric mortality 0.684336 gastric endoscopy 0.658667 sporadic gastric adenomas 0.698707 Low serum pepsinogen 0.556585 case-control studies 0.567568 coincident decrease 0.54268 gastric cancer mortality 0.786779 intestinal metaplasia 0.542939 tissue gastric lymphoma 0.689624 gastric lymphoma. 0.665709 screening study 0.547045 duodenal ulcer disease 0.55893	standard cut-off values 0.552573 familial adenomatous polyposis 0.560734 single referral center 0.552547 gastric body 0.665835 proton pump inhibitors 0.55184 common cancer 0.560082 national program 0.560036 screening program 0.548065 noncardia gastric carcinoma 0.695412 classifies H. pylori 0.563321 diffuse type 0.542605 gastric carcinoma 0.707449 indigestion change pepsinogen 0.555323 gastric cancer 0.921375 type gastric cancer 0.702788 intestinal type 0.629856 striking decrease 0.543352 pernicious anemia 0.567146 chronic atrophic gastritis 0.574769 gastric cancer. 0.695414 stomach cancer 0.550691 nonpolyposis colon cancer 0.578666 twofold decrease 0.54109 Gastric adenocarcinomas 0.6758	CLICK HERE
1423	National Cancer Institute	Html	en	Oral Cavity and Oropharyngeal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing cancer of the lip or mouth and about approaches that may help in the prevention of this disease.	large cohort study 0.376766 oral cavity accounts 0.552607 Papua New Guinea 0.380571 French Guiana 0.34684 United States 0.44201 age-adjusted incidence 0.362072 100,000 0.359624 areca nut. 0.346627 high alcohol intake 0.39156 epidemiologic studies 0.378316 oropharyngeal cancers 0.387229 5-year survival rate 0.495328 oropharyngeal cancer. 0.45765 personal history 0.348827 Human papillomavirus 0.350206 oral cavity cancer 0.797428 future primary cancer 0.407597 betel quid 0.499314 tobacco 0.395457 stage-specific survival rates 0.38041 important risk factor 0.379095 World Standard Population 0.382887 regional lymph node 0.379129 U.S. incidence 0.3611	worldwide incidence rate 0.411302 Squamous cell carcinoma 0.382371 risk factors 0.357771 elevated risk 0.400796 betel-quid chewing 0.354181 distinct diseases 0.351665 relative risk 0.346929 mortality rate 0.410597 common pharyngeal cancer. 0.386214 pharynx cancer 0.364625 persons 0.372394 Gutka chewing 0.349427 commonly available forms 0.391505 smokeless tobacco 0.374103 oral mucosal 0.411667 high risk 0.355532 neck region 0.347305 oral cavity 0.982405 oropharyngeal cancer 0.482897 mortality estimates 0.39101 added tobacco 0.357539 betel leaf 0.365996 mortality rates 0.364344	CLICK HERE
1461	National Cancer Institute	Html	en	Vaginal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of vaginal cancer.	ongoing clinical trials 0.85552 long time span 0.761526 vaginal carcinoma 0.951107 vaginal wall involvement 0.883409 prior hysterectomy 0.778571 vaginal cancer 0.818887 vaginal cancer. 0.807751 available staging tests 0.778942 upper vaginal lesions 0.893311 Regional lymph nodes 0.757227 concurrent chemotherapy 0.764946 clear cell carcinomas 0.789213 cervical cancer 0.899035 Vaginal adenosis 0.826312 vaginal carcinomas 0.846251 vaginal SCC patients 0.90084 treatment approaches 0.767338 women 0.767592 treatment 0.85362 AJCC staging system. 0.759072 vaginal vault 0.831513 case series 0.90433 utero DES exposure 0.803909 apical vagina 0.754218 vaginal intraepithelial neoplasia 0.874302	external-beam radiation 0.754266 treatment planning 0.776769 clear cell carcinoma 0.966645 clear cell adenocarcinoma 0.790722 vaginal cancers 0.837225 local modality therapies 0.783604 cervical cancer management 0.790278 noninvasive squamous cell 0.774465 relative efficacy 0.761447 Gy tumor dose 0.754907 vaginal clear cell 0.868627 disease 0.778359 precise staging criteria 0.772344 local control 0.818953 utero exposure 0.878366 Early stage tumors 0.815533 cervical intraepithelial neoplasia 0.792254 small case series 0.758482 insufficient dose penetration 0.75402 American Joint Committee 0.782817 locally advanced tumors 0.766917 Cervical Cancer Treatment 0.817322 surgical treatment options 0.788171 standard treatment 0.795403	CLICK HERE
1659	National Cancer Institute	Html	en	Genetics of Skin Cancer (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genetics of skin cancer — basal cell carcinoma, squamous cell carcinoma, and melanoma — including information about specific gene mutations and related cancer syndromes. The summary also contains information about interventions that may influence the risk of developing skin cancer in individuals who may be genetically susceptible to these syndromes.	nevoid BCC syndrome 0.361131 skin cancer 0.445517 subsequent basal cell 0.405637 cell types 0.363322 inbasal cell carcinoma 0.372942 cell naevus syndrome 0.392978 infundibulocystic basal cell 0.393823 multiple basal cell 0.462541 nevoid basal-cell carcinoma 0.367205 basal-cell carcinoma syndrome 0.380703 naevoid basal cell 0.446514 cell nevus syndrome 0.483609 keratocystic odontogenic tumors 0.361624 nevoid basal cell 0.773092 multiple nevoid basal 0.40348 carcinoma syndrome lead 0.369766 Br J Dermatol 0.370287 basal cell tumor 0.411053 basal cell keratinocytes 0.422712 basal cell carcinoma 0.952732 et al. 0.483994 human basal cell 0.406014 Arch Dermatol 0.379242 basal cell skin 0.440681 cell nevoid syndrome 0.373946	cell skin cancer 0.406713 PUBMED Abstract 0.466137 Eur Acad Dermatol 0.357296 pathogenic variants 0.416348 familial basal cell 0.406823 sporadic basal cell 0.406156 squamous cell skin 0.357805 gorlin syndrome 0.402395 BASAL CELL TUMOURS 0.39834 Med Genet 0.412537 Abstract 0.519599 invasive basal cell 0.401542 basal cell nevus 0.538871 basal keratinocytes 0.391532 germline pathogenic variants 0.357761 basal cell naevus 0.432813 cell carcinoma syndrome 0.750335 basal cell carcinomas 0.628359 basal cell cancer 0.436245 nonmelanoma skin cancer 0.368108 Hum Genet 0.375007 basal layer 0.373145 Acad Dermatol 0.401088 early-onset basal cell 0.406919	CLICK HERE
1827	National Cancer Institute	Html	es	Tratamiento de la leucemia linfocítica crónica (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfocítica crónica.	genetic features predict 0.402765 Davis Z 0.402966 Exp Med 0.403766 with chronic lymphocytic 0.453469 B-cell chronic lymphocytic 0.404152 Hamblin TJ 0.403993 Montserrat E 0.403191 patients with rai 0.4028 lymphocytic leukemia reveals 0.403683 O'Brien S 0.403439 Keating MJ 0.403308 granular lymphocytes 0.404274 patients with chronic 0.453881 terapia inmediata versus 0.402689 CD38 expression 0.404463 ZAP-70 expression 0.403246 La LLC 0.412195 cell chronic lymphocytic 0.409866 Lymphocytic Leukemia updating 0.403993 patients with 0.466989 early-stage chronic lymphocytic 0.403314 gene expression 0.402974 Shanafelt TD 0.404951 International Workshop 0.403274 leukemia treated with 0.403613	granular lymphocyte leukemia 0.40409 versus clorambucilo 0.403972 French Cooperative Group 0.402864 monoclonal b-cell lymphocytosis 0.404973 Loughran TP Jr 0.403102 prognostic features 0.40312 leukemia with 0.405469 immunoglobulin mutation genotype 0.402773 lymphocytic leukemia from 0.403953 high-risk features such 0.40263 chronic lymphoid leukemia 0.404328 granular lymphocytic leukemia 0.403581 VH mutation status 0.402969 T-cell chronic lymphocytic 0.403416 large granular lymphocyte 0.403546 Clin Oncol 0.457605 Catovsky D 0.410385 mutation status 0.410696 chronic lymphocytic leukemia 0.989679 chronic lymphocytic leukaemia 0.467178 with chronic lymphoid 0.403309 lymphocyte leukemia with 0.403276 following chemoimmunotherapy with 0.404045 features such as 0.402637	CLICK HERE
1913	National Cancer Institute	Html	es	Tratamiento del cáncer de testículo (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de testículo.	estadio is 0.441617 siguientes procedimientos 0.287311 células madre 0.729809 orquiectomía inguinal 0.910567 Testicular Cancer 0.25752 Pronóstico intermedio 0.226624 tubos minúsculos 0.238436 menor frecuencia 0.216803 rayos x 0.232109 sistema urinario masculino 0.265452 Pronóstico adverso 0.227528 estadio ib 0.342087 estadio ia 0.340936 largo plazo 0.339676 enlace drugs approved 0.310101 ondas sonoras 0.236752 National Cancer Institute 0.216079	siguientes riesgos 0.21354 Instituto Nacional 0.230763 estadio iiia 0.333884 PDQ Tratamiento 0.233897 estadio iiic 0.330798 estadio iia 0.338825 estadio iic 0.337012 coriónica humana beta 0.516427 Physician Data Query 0.263764 distinta manera 0.239745 Antecedentes familiares 0.232829 túbulos minúsculos 0.234263 glándulas sexuales masculinas 0.271775 ganglios linfáticos distantes 0.736212 toma imágenes 0.223821 siguientes pruebas 0.248918	CLICK HERE
1919	National Cancer Institute	Html	es	Tratamiento del cáncer primario de hígado en adultos (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer primario de hígado en adultos.	pequeñas incisiones 0.360209 Cirujano oncólogo 0.35403 Clinic Liver Cancer 0.895614 siguientes procedimientos 0.409083 siguientes aspectos 0.386863 pequeña cantidad 0.337477 tratamiento causa 0.413554 siguientes métodos 0.411504 siguientes especialistas 0.376622 rayos x 0.47678 imagen tridimensional 3-D 0.372363 lesiones duraderas 0.36475 sustancias dañinas 0.379531 cuerpo usa 0.466772 ondas sonoras 0.366833	triple fase 0.491781 National Cancer Institute 0.334891 siguientes riesgos 0.332851 sección superior derecha 0.425641 Instituto Nacional 0.432945 siguientes grupos 0.397061 PDQ Tratamiento 0.382467 siguientes puntos 0.412752 estadificación barcelona clinic 0.916026 hepatitis c 0.503388 Drugs Approved 0.34614 Physician Data Query 0.434214 Barcelona Clinic Liver 0.903635 pequeña incisión 0.343621 siguientes enlaces 0.343192	CLICK HERE
2017	National Cancer Institute	Html	es	Aspectos generales de la prevención del cáncer (PDQ®)–Versión para profesionales de salud	Información general sobre la prevención del cáncer y descripciones de conceptos usados en sumarios específicos sobre la prevención del cáncer.	régimen alimentario frente 0.52739 Cancer genes 0.521607 World Cancer Research 0.569873 Iowa Women Health 0.545115 Australian Cancer 0.523867 accessed august 0.547411 Sin embargo 0.591735 American Cancer Society 0.574381 largo plazo 0.544542 radiación solar uv 0.530547 Low Levels 0.551207 Cancer Mortality Among 0.527608 Assess Health Risks 0.519239 PHS II 0.544279 Estados Unidos 0.634682 health risks from 0.598572 menor riesgo 0.576825 PDQ Prevención 0.995577 Women’s Health Study 0.522268 Cancer Epidemiology 0.523152 detección produciría casos 0.524098 Cancer Risk Factors 0.532188 ionizing radiation 0.693544 cancer prevention 0.543238 United States 0.521643	Fraumeni JF Jr 0.580264 Cancer Facts 0.529494 radiation exposure 0.542511 Radiation Protection 0.539013 vitamina b12 versus 0.522212 Health Study 0.549664 características únicas 0.524754 Cancer Research 0.60501 Ionizing Radiation Exposure 0.534695 vitamina b12 0.53218 Cancer Prevention Trial 0.532033 risks from exposure 0.603319 Clin Oncol 0.531778 vitamina b6 0.531978 Ionizing Radiation VII 0.531441 radiación uv 0.526208 National Research Council 0.54637 Arch Intern Med 0.544117 cuello uterino 0.588712 Cancer Biol 0.523757 National Academies 0.527165 National Council 0.522058 cancer risk 0.595574 National Research 0.546614	CLICK HERE
2112	National Cancer Institute	Html	es	Prevención del cáncer de hígado (hepatocelular) (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer hepatocelular y sobre las investigaciones dirigidas a prevenir esta enfermedad.	hepatitis a 0.691582 hepatitis b 0.976325 hepatitis c 0.953816 siguientes factores 0.63541 voluntarios sanos 0.537145 Physician Data Query 0.668307 Estados Unidos 0.777756 suficiente ejercicio 0.541596 prevención revisa 0.539969 sustancias dañinas 0.552371	PDQ Prevención 0.566207 hepatitis aguda 0.682178 cuerpo usa 0.546831 National Cancer Institute 0.544327 siguientes riesgos 0.530546 mediana edad 0.550051 siguientes sumarios 0.587942 Instituto Nacional 0.581698 múltiples funciones 0.548976	CLICK HERE
17221	National Cancer Institute	Html	es	Exámenes de detección del cáncer de tiroides (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar el cáncer de tiroides.	Thyroid Cancer Mortality 0.4611 accessed august 0.42342 anual promedio 0.41796 during first screening 0.416166 American Cancer Society 0.461311 South Korea 0.449276 Ahn HS 0.443564 Thyroid Cancer Screening 0.461683 Preventive Services Task 0.480652 Instituto Nacional 0.427903 laríngeo recurrente causa 0.41545 PDQ Exámenes 0.439936 Estados Unidos 0.575638 Natl Cancer Inst 0.465908 Korea Community Health 0.446353 Thyroid Cancer Incidence 0.51938 US Preventive Services 0.435857 Cancer Screening Guidelines 0.440415 papillary thyroid carcinoma 0.44378 nódulos tiroideos 0.434456 SEER Cancer Statistics 0.432375 Cancer Research UK 0.460382 cohort study 0.41948 United States Preventive 0.414458 National Cancer 0.484654	United States 0.420839 Cancer Incidence Statistics 0.43264 thyroid cancer 0.948734 Cancer Facts 0.42824 korea's thyroid-cancer 0.432482 aumento anual promedio 0.415042 Managing incidental thyroid 0.44237 Welch HG 0.420771 Reporting Thyroid Cytopathology 0.44067 National Cancer Institute 0.466646 American College 0.415528 Sosa JA 0.420591 South Korea Thyroid-Cancer 0.421513 PDQ Tratamiento 0.429473 Kim HJ 0.417652 Community Health Survey 0.4356 Services Task Force 0.479733 Thyroid tumors 0.437792 Korea Cancer Registry 0.440985 PDQ Genetics 0.426977 Incidental Thyroid Findings 0.439567 Reino Unido 0.431597 Statistics Korea 0.417551 BMC Cancer 0.427511	CLICK HERE